(Q38646886)

5 September 2017

Ongoing challenges in the diagnosis of hepatocellular carcinoma (English)

1 reference

5 September 2017

Fabio Piscaglia

4

0 references

author name string

Eleonora Terzi

series ordinal

1

1 reference

PubMed ID

26603785

5 September 2017

Veronica Salvatore

series ordinal

2

1 reference

PubMed ID

26603785

5 September 2017

Giulia Negrini

series ordinal

3

1 reference

5 September 2017

24 November 2015

1 reference

Expert Review of Gastroenterology & Hepatology

5 September 2017

1 reference

5 September 2017

10

1 reference

5 September 2017

4

1 reference

5 September 2017

451-463

1 reference

MR imaging of hypervascular lesions in the cirrhotic liver: a diagnostic dilemma.

5 September 2017

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Management of solitary 1 cm to 2 cm liver nodules in patients with compensated cirrhosis: a decision analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Characterization of primary and recurrent nodules in liver cirrhosis using contrast-enhanced ultrasound: which vascular criteria should be adopted?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Which is the best MRI marker of malignancy for atypical cirrhotic nodules: hypointensity in hepatobiliary phase alone or combined with other features? Classification after Gd-EOB-DTPA administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Consensus Development from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Hypovascular nodules in patients with chronic liver disease: risk factors for development of hypervascular hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Hypovascular hepatic nodules showing hypointense on the hepatobiliary-phase image of Gd-EOB-DTPA-enhanced MRI to develop a hypervascular hepatocellular carcinoma: a nationwide retrospective study on their natural course and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Was Hypervascular Hepatocellular Carcinoma Visible on Previous Gadoxetic Acid-Enhanced Magnetic Resonance Images?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Ultrasound-guided cutting biopsy for the diagnosis of hepatocellular carcinoma — a study based on 420 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Needle track seeding of primary and secondary liver carcinoma after percutaneous liver biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Needle-tract implantation in hepatocellular carcinoma: frequency and CT findings after biopsy with a 19.5-gauge automated biopsy gun.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Ultrasound guided fine needle biopsy of early hepatocellular carcinoma complicating liver cirrhosis: a multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Is tumor biopsy necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

The combination of type I interferon and ribavirin has an inhibitory effect on mouse hepatitis virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Transient hepatic attenuation differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Radiological features of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Prognosis of hepatocellular carcinoma: the BCLC staging classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Ultrasound molecular imaging of VEGFR2 in a rat prostate tumor model using BR55.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Use of VEGFR-2 targeted ultrasound contrast agent for the early evaluation of response to sorafenib in a mouse model of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Contrast-enhanced ultrasound for liver imaging: recent advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Detailed analysis of temporal features on contrast enhanced ultrasound may help differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma in cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Long-term outcome of liver transplantation for combined hepatocellular carcinoma and cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Improved post-transplant survival in the United States for patients with cholangiocarcinoma after 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: a Spanish matched cohort multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Clinical and economical impact of 2010 AASLD guidelines for the diagnosis of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Off-label use of ultrasound contrast agents for abdominal imaging in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Differential diagnosis of hepatic tumors: value of contrast-enhanced harmonic sonography using the newly developed contrast agent, Sonazoid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Grading of hypervascular hepatocellular carcinoma using late phase of contrast enhanced sonography—A prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Evaluation of hepatocellular carcinoma using SonoVue, a second generation ultrasound contrast agent: correlation with cellular differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Correlation between enhancement pattern of hepatocellular carcinoma on real-time contrast-enhanced ultrasound and tumour cellular differentiation on histopathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Value of post-vascular phase (Kupffer imaging) by contrast-enhanced ultrasonography using Sonazoid in the detection of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Hepatocellular carcinoma tumour markers: current role and expectations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Diagnosis accuracy of serum glypican-3 in patients with hepatocellular carcinoma: a systematic review with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Model to estimate survival in ambulatory patients with hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Identification of metastasis-related microRNAs in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

A Seven-microRNA Expression Signature Predicts Survival in Hepatocellular Carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Sonazoid-Enhanced Ultrasonography for Diagnosis of Hepatic Malignancies: Comparison with Contrast-Enhanced CT

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Staging Hepatocellular Carcinoma by a Novel Scoring System (BALAD Score) Based on Serum Markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Non-invasive diagnosis of hepatocellular carcinoma ⩽2cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1124758

10.1586/17474124.2016.1124758

21 January 2018

Identifiers

DOI

1 reference

5 September 2017

1 reference

PubMed ID

26603785